KKKristen Marie Krysko

Kristen Marie Krysko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristen Marie Krysko has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peripartum mental illness in serial pregnancies in mothers with multiple sclerosis and other chronic diseases

    by Ruth Ann Marrie, James M. Bolton, Vicki Ling, Charles N. Bernstein, Kristen M. Krysko, Ping Li, Dalia L. Rotstein, Karma Deakin-Harb, Colleen J. Maxwell

    Background: Mothers with multiple sclerosis have an elevated risk of peripartum mental illness, but changes in risk across serial pregnancies are unknown. Objectives: We compared the incidence, lifetime prevalence, and prevalence of peripartum mental illness requiring care (‘active’) among mothers with multiple sclerosis and other conditions. Methods: Using population-based administrative data from Ontario, Canada, we identified 549,010 mothers with multiple sclerosis (922), epilepsy (3486), inflammatory bowel disease (3008), diabetes (5991), and without these diseases (comparators, 535,603) who had two live births. Using validated definitions, we estimated incidence and prevalence of mental illness (any, depression, anxiety, bipolar disorder, psychosis, substance use, suicide attempt) during serial peripartum periods. We compared rates using Poisson models. Results: Among mothers with multiple sclerosis, any incident mental illness affected 20.4% during the first peripartum period and 11.6% in the second; one-quarter received any mental illness care (active prevalence) during the second peripartum period. Post-adjustment, mothers with multiple sclerosis had a higher active prevalence of depression (prevalence ratio 1.19; 1.04–1.35), anxiety (prevalence ratio 1.21; 1.09–1.35), and bipolar disorder (prevalence ratio 1.48; 1.28–1.71) than comparators, as did mothers with epilepsy, inflammatory bowel disease and diabetes. Conclusions: Mothers with multiple sclerosis, epilepsy, inflammatory bowel disease and diabetes share an elevated risk of mental illness in serial pregnancies.

  • Reproductive health in multiple sclerosis patients: overcoming challenges and improving patient care

    by Sarah MacIsaac, Kristen M. Krysko

    Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that most commonly affects women of reproductive age. Historically, management of people with MS (pwMS) who may...

  • Open Access

    High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial

    by Vinicius A Schoeps, Raviola Murataj, Akash Virupakshaiah, Carson E Moseley, Kristen M Krysko, Bardia Nourbakhsh, Ferhan Qureshi, Roland Henry, Emmanuelle Waubant

    To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.

  • Open Access

    Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

    by Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, et al.

    Objective: To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods: Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. Results: A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety‐three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52–1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20–0.57; rate ratio: 0.38, 95% CI = 0.21–0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09–0.37; rate ratio: 0.21, 95% CI = 0.10–0.44) ( p < 0.001). Adjusted number needed to treat in person‐years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03–8.69) and infusion over injectable 1.43 (95% CI = 1.00–3.88). Interpretation: Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long‐term safety data are required. ANN NEUROL 2026;99:715–729


  • Open Access

    Risk factors for incident peripartum mental illness in multiple sclerosis

    by Ruth Ann Marrie, James M Bolton, Vicki Ling, Charles N Bernstein, Kristen M Krysko, Ping Li, Kyla A McKay, Neda Razaz, Dalia L Rotstein, Karma Deakin-Harb, et al.

    Background: Mothers with MS face an increased incidence and prevalence of peripartum mental illness as compared to mothers without MS. Objective: To determine the factors associated with the risk of peripartum mental illness among mothers with MS. Methods: We identified mothers with MS with live births between 2002 and 2019 using linked population-based administrative data from Ontario, Canada. Using validated definitions, we estimated the incidence of mental illness (depression, anxiety, bipolar disorder) from conception through the first post-partum year (peripartum period). We used multivariable Poisson regression to assess the association between age, delivery year, area-level deprivation (Ontario Marginalization Index), disease duration, disability, and comorbidity and incidence of peripartum mental illness. Results: Among 1745 mothers with MS, the mean (SD) age at conception was 31.2 (4.8) years. Mothers living in communities that lacked cohesion had increased rates of peripartum depression (incidence rate ratio [IRR] 1.25; 1.11–1.42) and anxiety (IRR 1.20; 1.07–1.33). Elevated MS disability level was associated with elevated peripartum depression rates (IRR 1.51; 1.12–2.04). Conclusion: Higher area-level deprivation and disability levels are associated with an increased incidence of peripartum mental illness. These findings may assist clinicians in identifying women with MS who may benefit from peripartum mental health support.

  • Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis

    by Kristen M. Krysko, Michael Waltz, Tanuja Chitnis, Bianca Weinstock-Guttman, Gregory S. Aaen, Anita Belman, Leslie A. Benson, Mark P. Gorman, Timothy E. Lotze, Soe S. Mar, et al.

    Sex steroid hormones have been demonstrated to affect the immune system in multiple sclerosis (MS), and puberty may trigger MS activity. We aimed to evaluate the association between menarche and disease course in pediatric MS through comparison of relapse rates across premenarche, perimenarche, and postmenarche periods. This is a retrospective analysis of a prospectively followed female cohort with pediatric-onset MS in the US Network of Pediatric MS Centers database. Perimenarche was considered the period from 1 year before to 1 year after the estimated menarche date based on menarche integer age. Relapses were collected prospectively. Negative binomial and repeated-measures Cox regression models were used to assess the association of pubertal development stage with relapse rate, adjusted for race, body mass index, and disease-modifying therapy (DMT). Of 736 participants (all female; mean onset age 14.4 ± 2.8 years; mean menarche age 11.6 ± 1.4 years), onset was in premenarche in 73, perimenarche in 112 (± 1 year of menarche), and postmenarche in 551. The median time of MS onset was 2.8 years after menarche. Most (86%) were exposed to DMT in follow-up. In adjusted negative binomial analysis, the annualized relapse rate during premenarche was 0.43, perimenarche was 0.65, and postmenarche was 0.43 (premenarche rate ratio [RR] 1.00 (95% CI 0.70-1.43) and perimenarche RR 1.52 (95% CI 1.16-1.99), compared with reference of postmenarche, p = 0.0049. In adjusted repeated-events Cox regression analysis, there was increased hazard to relapse in perimenarche and postmenarche compared with premenarche (perimenarche hazard ratio [HR] 1.78 [95% CI 1.17-2.70] and postmenarche HR 1.67 [95% CI 1.12-2.50], compared with reference of premenarche, p = 0.025). In this analysis, use of oral and infusion DMTs significantly lowered the relapse hazard compared with periods of no DMT use (injectable HR 0.98 [95% CI 0.83-1.15], oral HR 0.48 [95% CI 0.37-0.61], and infusion HR 0.24 [95% CI 0.18-0.31], compared with no DMT, p < 0.001). Onset of puberty may be a time of increase in disease activity and may require consideration of a change in therapeutic approach. Menarche age was used as a surrogate for puberty, and future studies measuring sex steroid hormones may be informative.


  • Open Access

    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada

    by Ruth Ann Marrie, James Bolton, Yushu (Vicki) Ling, Charles Bernstein, Kristen M. Krysko, Ping Li, Kyla A. Mckay, Priscila Pequeno, Neda Razaz, Dalia Rotstein, et al.

    Peripartum mood and anxiety disorders constitute the most frequent form of maternal morbidity in the general population, but little is known about peripartum mental illness in mothers with multiple sclerosis (MS). We compared the incidence and prevalence of peripartum mental illness among mothers with MS, epilepsy, inflammatory bowel disease (IBD), and diabetes and women without these conditions. Using linked population-based administrative health data from ON, Canada, we conducted a cohort study of mothers with MS, epilepsy, IBD, and diabetes and without these diseases (comparators) who had a live birth with index dates, defined as 1 year before conception, between 2002 and 2017. Using validated definitions, we estimated the incidence and prevalence of mental illness (any, depression, anxiety, bipolar disorder, psychosis, substance use, suicide attempt) during the prenatal (PN) period (from conception to birth) and 3 years postpartum. We compared incidence and prevalence estimates between cohorts using simple incidence ratios (IRs) and prevalence ratios with 95% CIs and using Poisson regression models adjusting for confounders. We included 894,852 mothers (1,745 with MS; 5,954 with epilepsy; 4,924 with IBD; 13,002 with diabetes; 869,227 comparators). At conception, the mean (SD) maternal age was 28.6 (5.7) years. Any incident mental illness affected 8.4% of mothers with MS prenatally and 14.2% during the first postpartum year; depression and anxiety were the most common incident disorders. The first postpartum year was a higher risk period than the PN period (any mental illness IR 1.27; 95% CI 1.08-1.50). After adjustment, mothers with MS had an increased incidence of any mental illness during the PN (IR 1.26; 95% CI 1.11-1.44) and postpartum (IR 1.33; 95% CI 1.20-1.47, first postpartum year) periods than comparator mothers. Similarly, mothers with MS had an increased incidence of all specific mental illnesses except suicide attempt during the PN period vs comparator mothers. Any prevalent mental illness affected 42% of mothers with MS prenatally and 50.3% in the first postpartum year. Mothers with MS had an elevated incidence and prevalence of peripartum mental illness compared with comparator mothers, although residual confounding cannot be excluded. These findings emphasize the need for preventive interventions and early treatment of mental illness.


  • Open Access

    Cesarian sections in women with multiple sclerosis: A Canadian prospective pregnancy study

    by Dessa Sadovnick, Maria Criscuoli, Irene Yee, Robert Carruthers, Virginia Devonshire, Penelope Smyth, Kristen M Krysko

    Background: An increasing number of women with multiple sclerosis (wMS) are considering pregnancy. Prior studies suggest increased rate of elective cesarian sections (C-sections) in wMS.Methods: The Canadian Multiple Sclerosis Pregnancy Study (CANPREG-MS) is a prospective study on pregnant wMS. This report shows comparisons between (i) CANPREG-MS wMS delivered by C-section and the general population and (ii) C-section and vaginal deliveries in this study cohort.Results: CANPREG-MS has resulted in 170 deliveries with 63 by C-section. The proportion with C-sections in CANPREG-MS (37.1%) was significantly higher than that for the Canadian population (28%) ( p = .0085). The majority (66.7%) of C-sections were not planned, and typically were performed for obstetrical indications. C-sections were performed at an earlier gestational age than vaginal deliveries, although birthweight did not differ by mode of delivery in wMS. MS relapses (3.2%) and pseudo-relapses (3.2%) were rare in the first month after C-section deliveries, regardless of disease modifying therapy decisions during gestation and postpartum.Conclusions: C-sections were more common in wMS than the general population, but few were because of maternal MS. CANPREG-MS provides informative data for pregnancies in wMS with well-managed and relatively mild disease. This information is helpful to obstetrical and MS healthcare providers.